Digital Transformation of a Biopharma Quality Control Lab

Significance of the Topic

The move toward a fully digital biopharmaceutical quality control laboratory addresses key regulatory pressures for paperless operations while meeting industry goals for faster turnaround, consistent data quality, and cost efficiency. Digital tools also enhance sample traceability, resource management, and audit readiness, all critical in highly regulated environments.

Objectives and Study Overview

This application note demonstrates the deployment of a cloud-based chromatography data system (OpenLab CDS) and laboratory information management system (SLIMS) to support monoclonal antibody (mAb) release testing. A small-scale QC lab model was built to run two liquid chromatography (LC) workflows—aggregation and charge variant analysis—on dedicated Agilent 1290 Infinity II systems. The primary aim was to illustrate an end-to-end digital workflow from sample submission to final reporting with minimal disruption to existing operations.

Methodology

A corporate network linked two Microsoft Azure servers hosting OpenLab CDS Client/Server 2.7 and SLIMS 6.9. Local instrument control was provided by an Agilent instrument controller (AIC). Sample scheduling and sequence management were handled by the Sample Scheduler for OpenLab. SLIMS was configured to manage sample orders, inventory, resource tracking, and digital standard operating procedures (SOPs) for mobile phase preparation. Protocol steps in SLIMS automatically deducted consumables from the cloud-based inventory and guided users through sample processing.

Instrumentation

• LC-1 (Aggregation Analysis): Agilent 1290 Infinity II bio high-speed pump, multisampler with sample cooler, multicolumn thermostat with bio heat exchanger, diode array detector
• LC-2 (Charge Variant Analysis): Agilent 1290 Infinity II bio flexible pump, multisampler with sample cooler, multicolumn thermostat with bio heat exchanger, diode array detector
• Software Platforms: SLIMS 6.9, OpenLab CDS Client/Server 2.7, Sample Scheduler for OpenLab 2.7
• Cloud Infrastructure: Two Microsoft Azure servers for OpenLab CDS and SLIMS

Main Results and Discussion

Two mAb batches were processed through identical digital workflows for aggregation and charge variant testing. SLIMS captured sample details, managed reagents and column inventories, and launched the appropriate OpenLab CDS methods directly from the LIMS interface. All experimental steps, from mobile phase preparation to sequence execution, were recorded electronically. Results were evaluated against preset CQA specifications (aggregate area ≤1 %, acidic variants 15–25 %, basic variants 10–15 %). One batch passed all criteria, while the second batch showed out-of-specification acid and basic variants and triggered automated warnings. All data, method files, reports, and audit trails were securely archived on the OpenLab Server with versioning for regulatory compliance.

Benefits and Practical Applications

The integrated cloud-based platform delivered a seamless digital QC workflow with:

• Instant sample submission and method assignment from SLIMS to OpenLab CDS
• Automated inventory control and reagent expiration tracking
• Digital SOPs that reduce human error and ensure procedural consistency
• Real-time result evaluation with automatic OOS alerts and decision logging
• Centralized data storage with secure versioning for audit readiness

Future Trends and Applications

Looking ahead, deeper integration of artificial intelligence for chromatographic method development, predictive maintenance of instruments, and advanced analytics will further enhance lab efficiency. Expanded cloud services may support multi-omics data integration and remote collaboration, while digital twin models of QC workflows could optimize resource allocation and lead times.

Conclusion

This study highlights how combining cloud-hosted OpenLab CDS and SLIMS can transform a biopharma QC lab into a fully digital operation. The solution supports regulatory compliance, improves turnaround times, reduces manual errors, and provides comprehensive data traceability—all with minimal operational disruption.

References

• Facts About the Current Good Manufacturing Practices (CGMP). U.S. FDA.
• ICH Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products.
• Bian Y. Charge Variant and Aggregation Analysis of Innovator and Biosimilars of Rituximab. Agilent Technologies Application Note 5994-1496EN, 2019.